Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.gsk-india.com | |
Market Cap | 26,149.52 Cr. | |
Enterprise Value(EV) | 23,604.02 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 100.04 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 15.39 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 29.26 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 157.19 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 9.80 | Calculated using Price: 1,540.00 |
Dividend Yield | 5.83 | Period Ending 2021-03 |
No. of Shares Subscribed | 16.94 Cr. | 169,406,034 Shares |
FaceValue | 10 | |
Company Profile | ||
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. With the combined heritage of Glaxo Wellcome plc and SmithKline Beecham plc, the company has played a pivotal role in the growth of the healthcare industry for almost a century. GSK has been a leader in India since inception, with a history replete with breakthrough innovations. Through the years, it has set benchmarks in conducting business responsibly, including the ways in which it research, develop, sell, and market its products. The company is headquartered in Mumbai with various regional and sales hubs across the country. The company has made substantial investments in one large manufacturing facility in Nashik, in the state of Maharashtra. Business area of the company The company is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company’s Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment. Products
Award and recognition 2017:
2018:
2019:
2020:
Milestones
|
1 Day |
|
+1.06% |
1 Week |
|
+3.24% |
1 Month |
|
-6.21% |
3 Month |
|
-1.63% |
6 Month |
|
-5.90% |
1 Year |
|
+5.43% |
2 Year |
|
+12.19% |
5 Year |
|
+26.11% |
10 Year |
|
+50.41% |
9 years | 2012-12 | 2013-12 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 28.50 | 24.10 | 24.95 | 18.75 | 16.08 | 17.26 | 21.22 | 4.71 | 21.58 | |
Return on Capital Employed (%) | 42.24 | 35.54 | 39.53 | 28.81 | 24.39 | 26.56 | 32.54 | 15.76 | 33.38 | |
Return on Assets (%) | 18.82 | 15.95 | 15.44 | 7.84 | 5.16 | 4.93 | 5.77 | 1.72 | 11.87 |
Particulars | 10 years | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 2,007 | 1,990 | 1,829 | 2,183 | 2,007 | 2,057 | 2,140 | 1,821 | 1,499 | 2,663 | |
Non Curr. Liab. | 158 | 159 | 197 | 3,498 | 3,700 | 2,632 | 2,860 | 180 | 179 | 159 | |
Curr. Liab. | 836 | 889 | 1,107 | 784 | 881 | 2,949 | 2,804 | 1,022 | 1,332 | 1,698 | |
Minority Int. | |||||||||||
Equity & Liab. | 3,002 | 3,037 | 3,133 | 6,465 | 6,588 | 7,639 | 7,804 | 3,023 | 3,010 | 4,520 | |
Non Curr. Assets | 355 | 413 | 546 | 4,087 | 4,753 | 4,103 | 4,445 | 1,248 | 808 | 812 | |
Curr. Assets | 2,647 | 2,624 | 2,587 | 2,378 | 1,835 | 3,536 | 3,359 | 1,775 | 2,203 | 3,708 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 3,002 | 3,037 | 3,133 | 6,465 | 6,588 | 7,639 | 7,804 | 3,023 | 3,010 | 4,520 |
Particulars | 10 years | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 2,692 | 2,608 | 3,363 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 3,199 | 3,425 | |
Other Income | 224 | 222 | 259 | 123 | 73 | 55 | 102 | 79 | 111 | 76 | |
Total Income | 2,916 | 2,830 | 3,622 | 2,961 | 2,982 | 2,926 | 3,230 | 3,303 | 3,309 | 3,501 | |
Total Expenditure | -1,915 | -2,124 | -2,788 | -2,360 | -2,489 | -2,366 | -2,527 | -2,567 | -2,504 | -2,624 | |
PBIDT | 1,001 | 706 | 833 | 601 | 492 | 560 | 703 | 736 | 806 | 877 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -6 | -4 | -2 | |
Depreciation | -18 | -20 | -25 | -25 | -26 | -38 | -49 | -83 | -79 | -69 | |
Taxation | -272 | -230 | -279 | -202 | -174 | -189 | -237 | -213 | -192 | -409 | |
Exceptional Items | -148 | 26 | -52 | 2 | 46 | 18 | 29 | -341 | -173 | 12 | |
PAT | 562 | 482 | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 409 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 562 | 482 | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | |
Adjusted EPS | 33 | 28 | 28 | 22 | 20 | 21 | 26 | 6 | 21 | 100 |
Particulars | 10 years | 2011-12 Rs. Cr. | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 335 | 314 | 281 | 338 | 139 | 234 | 473 | 409 | 491 | 578 | |
Cash Fr. Inv. | 358 | -110 | 189 | 180 | 499 | 301 | -104 | -153 | -57 | 419 | |
Cash Fr. Finan. | -395 | -441 | -494 | -497 | -638 | -511 | -307 | -358 | -428 | -696 | |
Net Change | 299 | -237 | -24 | 21 | 0 | 24 | 62 | -102 | 6 | 300 | |
Cash & Cash Eqvt | 374 | 138 | 114 | 116 | 115 | 139 | 201 | 99 | 105 | 405 |
Fri, 20 May 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under regulation 39(3) as SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
Wed, 18 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication Advt relating Financial Results |
Tue, 17 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Annual Secretarial Compliance Report for the financial year ended March 31 2022 |
Fri, 20 May 2022 |
|
|
|
|
|